Skip to main content
Guangzhou LBP Medicine Science & Technology Co., Ltd. logo

Guangzhou LBP Medicine Science & Technology Co., Ltd. — Investor Relations & Filings

Ticker · 688393 ISIN · CNE1000043R4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2026-05-27 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 688393

About Guangzhou LBP Medicine Science & Technology Co., Ltd.

https://en.gzlbp.com/

Guangzhou LBP Medicine Science & Technology Co., Ltd. specializes in the research, development, and manufacturing of advanced pathological diagnostic products. The company provides integrated solutions across three primary technological platforms: liquid-based cytology (LBC), immunohistochemistry (IHC), and molecular diagnostics, including fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR). Its product portfolio features automated staining instruments, high-sensitivity reagents, and diagnostic kits for cancer screening and precision medicine, such as HPV testing and tumor marker detection. By focusing on the automation and standardization of pathology workflows, the company supports clinical laboratories and hospitals in improving diagnostic accuracy and efficiency. Its offerings encompass the entire diagnostic process from sample preparation to result analysis, catering to the evolving needs of modern pathology and personalized oncology.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an official announcement by Guangzhou Anbipin Pharmaceutical of its 2025 year-end dividend distribution details, including cash dividend per share, record/ex-dividend/payment dates, distribution plan, and tax withholding policies. This matches the “Notice of Dividend Amount” category.
2026-05-27 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official announcement by Guangzhou Anbipeng Medical Technology Co., Ltd. regarding the resolutions passed at its 2025 Annual General Meeting, including detailed voting results for each proposal. This aligns exactly with the definition for “Declaration of Voting Results & Voting Rights Announcements” (Code: DVA).
2026-05-20 Chinese
广东信达律师事务所关于广州安必平医药科技股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter (“法律意见书”) issued by an external law firm regarding the legality of the procedures for the company’s 2025 Annual General Meeting. It is not the actual AGM presentation/materials (AGM-R), nor a proxy solicitation statement (PSI) or any financial report. It does not fit any specific category such as 10-K, IR, ER, M&A, etc. It is an external legal certification filed as a regulatory/legal disclosure. Therefore, the appropriate classification is the catch-all “Regulatory Filings” category (RNS).
2026-05-20 Chinese
2025年年度股东会会议资料
AGM Information Classification · 100% confidence The document is titled as "2025年年度股东会会议资料" which translates to "2025 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda items, meeting instructions, proposals for shareholder approval, reports to be heard, and voting procedures for the 2025 AGM of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd. The content includes multiple proposals for shareholder approval such as the 2025 Annual Report, Board Work Report, Profit Distribution Plan, Stock Issuance Authorization, and remuneration plans, as well as reports to be heard like the Independent Director's Report. The document is clearly the set of materials prepared for the AGM meeting itself, not the annual report or other filings. It is comprehensive and over 11,000 characters, indicating it is the meeting materials, not just an announcement or a brief notice. Therefore, the correct classification is AGM Information (AGM-R).
2026-05-08 Chinese
第四届董事会独立董事专门会议第九次会议决议
Board/Management Information Classification · 85% confidence The document is a set of resolutions from an independent directors’ specialist meeting of the board, covering approvals for share issuance, cancellation of incentive shares, remuneration policies, and nomination of a new non-independent director. This is an internal board/management announcement rather than a full financial report, capital update, or regulatory filing, and it specifically deals with board-level decisions and a proposed board member. It best fits the Board/Management Information category (MANG).
2026-04-28 Chinese
2025年度董事会审计委员会履职情况报告
Governance Information Classification · 88% confidence The document is titled "2025年度董事会审计委员会履职情况报告" and details the audit committee’s composition, meetings held during the year, supervisory and evaluative activities, and overall governance oversight. It is not an external financial audit report nor a financial statement, but rather a governance report on board committee activities. This aligns with the "Governance Information" category (CGR) which covers reports on internal rules, board structures, and governance practices.
2026-04-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.